Outcomes Study with Hospital Clinico Metropolitano La Florida will test the efficacy of remote monitoring and remote insulin adjustments; Nipro to provide their latest FDA-cleared glucose meters, diagnostic supplies and enrollment support
RICHMOND, Va., Jan. 20, 2015 - ALR Technologies Inc. (ALRT) announced that Nipro Diagnostics, Inc. and Nipro Medical Corporation have agreed to participate in a clinical outcomes study to be conducted by ALRT and Hospital Clinico Metropolitano La Florida, one of the largest and most prestigious public hospitals in Santiago, Chile. Nipro will provide its latest blood glucose meter, TRUE METRIX, to all participants in the trial as well as diagnostic supplies such as blood glucose test strips and data management cables. In addition, Nipro employees will assist with subject enrollment and other logistical tasks related to the pilot. Subject enrollment in the pilot is due to begin early next year.
Hospital Clinico Metropolitano La Florida will enroll 100 of its insulin-requiring patients in the intervention arm of the study and 100 insulin-requiring patients in the control arm. The intervention group will utilize the Health-e-Connect System with IDAC for six months of treatment. Key data points for the study will include: average A1c reduction, adherence to medication and care plan, and physician and patient satisfaction. The trial will also survey patient satisfaction with the TRUE METRIX blood glucose monitoring system. For more information on the trials, go here:
Nipro Diagnostics Global Director of Professional and Clinical Services, Teri Sasse, said: "There is an urgent medical need in Chile and in Latin America to find diabetes solutions that can stem the rising tide of diabetes prevalence. By participating in this trial, we hope that we can assist Chilean public health authorities in testing innovative solutions using our diagnostic tools." Nipro Medical Corporation Diabetes Division Manager for Latin America, Raul Lozano adds "We are pleased that ALR Technologies and Hospital Clinico Metropolitano La Florida chose the new Nipro TRUE METRIX Blood Glucose Meter and we look forward to being an integral component to assist in improving patient outcomes and helping to reduce the cost of treating patients with diabetes in Chile and throughout Latin America".
ALRT's CEO Sidney Chan said: "We are honored to have Nipro as a partner in this important trial. Their diagnostic tools are ideal for this trial because of their high quality and accuracy. Nipro is displaying excellent corporate citizenship by their generous allocation of resources for this trial."
Nipro Diagnostics, Inc.: Based in Fort Lauderdale, Florida, Nipro Diagnostics, Inc. is a leading developer, manufacturer and marketer of diabetes monitoring and management products. The company offers a portfolio of high- quality blood glucose monitoring systems and diabetes management products available around the world. Nipro Diagnostics is the exclusive supplier of blood glucose monitoring systems, co-branded under the TRUE name, to the world's leading pharmacies, distributors and mail service providers. For more information, please visit: www.niprodiagnostics.com
Nipro Medical Corporation, with offices in every country in Latin America is a distributor of quality, cost affordable medical products. Divisions of Nipro Medical Corporation include Renal, Hospital, Laboratory, Diabetes, Endovascular, Cardiopulmonary, Medical Glass and Pharma. The TRUE METRIX Blood Glucose Meter from Nipro Diagnostics is the latest offering within the Diabetes Division.
ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases. ALRT has developed the FDA-cleared and HIPAA compliant Health-e-Connect System that collects data from blood glucose meters and uploads to a secure website. Trained Facilitators use the System to effect efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their quality goals. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. For more information, please visit: www.alrt.com
For more information, email us at
This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate", "expect", "anticipate", "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company's quarterly filings with the Securities Exchange.